NORTH West biotech company F2G has raised $30m (£18.8m) in an institutional fund-raising.F2G, based in Eccles, is a pioneer in discovering and developing drugs to treat life threatening fungal diseases. The latest fund-raising sees Advent Life Sciences and Novartis Bioventures join an existing syndicate of investors comprising Sunstone Capital, Merifin Capital, K Nominees and Astellas Venture Fund.The company will use the proceeds of the investment to move forward its advanced pre-clinical trials towards "in man studies". It ......for the full story register now for free or login below...